[{"question_number":"8","question":"An elderly man has been acting out his dreams, kicking his wife, and experiencing vivid visual hallucinations. His delirium workup was negative. What is the most likely diagnosis?","options":["Lewy body dementia","Alzheimer's disease","Corticobasal degeneration","Frontotemporal dementia"],"correct_answer":"A","correct_answer_text":"Lewy body dementia","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (Lewy body dementia) is correct because REM sleep behavior disorder with dream enactment, vivid visual hallucinations, cognitive fluctuations, and parkinsonism are core features meeting consensus criteria in over 75% of cases. Pathologically, alpha-synuclein aggregation in cortical and subcortical neurons produces Lewy bodies with cholinergic deficits explaining visual hallucinations and rapid eye movement sleep behavior disorder (RBD). Misconceptions often arise from confusing Alzheimer\u2019s visual misperceptions with true formed hallucinations. Studies show 50\u201360% of DLB patients develop RBD before cognitive decline (McKeith et al. 2017). Option B (Alzheimer\u2019s disease) typically presents with progressive memory impairment, amyloid plaques, tau neurofibrillary tangles, and absence of early RBD or well-formed visual hallucinations; hallucinations generally occur only in late stages in less than 30% of cases. Option C (corticobasal degeneration) features asymmetric rigidity, apraxia, cortical sensory loss, alien limb phenomenon, not visual hallucinations or RBD. Option D (frontotemporal dementia) presents with behavioral disinhibition, language variants, frontal atrophy, and lacks prominent visual hallucinations or REM sleep behaviors. In summary, only Lewy body dementia accounts for the specific triad of RBD, vivid visual hallucinations, and negative delirium workup supported by prevalence data and pathological studies.","conceptual_foundation":"Lewy body dementia involves both cortical and brainstem structures. The substantia nigra pars compacta, locus coeruleus, dorsal raphe, and pedunculopontine nuclei show alpha-synuclein inclusions. Cortical involvement affects temporal, parietal, and occipital lobes, leading to visuospatial deficits and hallucinations. Basal forebrain cholinergic neurons in the nucleus basalis of Meynert undergo degeneration, reducing acetylcholine in cortex and hippocampus. Embryologically, these brainstem nuclei derive from mesencephalic and rhombencephalic segments, with early vulnerability due to synuclein accumulation. Normal physiology includes synchronized REM atonia mediated by sublaterodorsal tegmental projections to spinal interneurons; dysfunction produces REM sleep behavior disorder. Related conditions include Parkinson disease dementia when motor signs precede cognition by one year. Historically, Lewy body dementia was differentiated from Alzheimer in the 1990s by McKeith et al. Landmark anatomical landmarks include the substantia nigra, amygdala, hippocampal formation, and visual association cortex, each significant for motor, cognitive, and perceptual symptoms. Understanding these regions clarifies how widespread synuclein pathology explains the diverse DLB clinical spectrum.","pathophysiology":"Lewy body dementia pathogenesis centers on misfolded alpha-synuclein aggregating into Lewy bodies and Lewy neurites in neurons. Normally soluble synuclein functions in synaptic vesicle regulation at presynaptic terminals. Mutations in SNCA, GBA, or LRRK2 genes increase aggregation propensity, with autosomal dominant or risk factor inheritance patterns. Aggregated synuclein triggers oxidative stress via mitochondrial dysfunction, cytochrome c release, and reactive oxygen species formation. Microglial activation releases proinflammatory cytokines, including TNF-alpha and IL-1beta, promoting neuronal injury. Loss of dopaminergic neurons in substantia nigra impairs nigrostriatal dopamine pathways; cholinergic basal forebrain neuron loss decreases cortical acetylcholine, driving cognitive and perceptual disturbances. Synuclein spread follows Braak stages, initially affecting lower brainstem, then limbic and neocortical regions over months to years. Compensatory upregulation of dopamine receptors occurs early, but decompensation yields parkinsonian features. Cholinergic receptor upregulation also fails to maintain normal cortical function. Energy deficits from mitochondrial impairment further exacerbate synaptic dysfunction and neuronal death.","clinical_manifestation":"Patients with Lewy body dementia typically develop REM sleep behavior disorder years before cognitive decline. Initial symptom onset median age is 70\u201375 years. Early features include dream enactment with vocalizations and complex movements, often injuring bed partners. Within months, patients report vivid visual hallucinations of people, animals, or objects in 65\u201380% of cases. Cognitive fluctuations present as acute episodes of confusion lasting hours to days. Neurological examination reveals parkinsonism characterized by bradykinesia, rigidity, and postural instability in up to 85%, asymmetric at onset. Elderly are more prone to severe hallucinations; males slightly more affected by RBD. Systemic manifestations include autonomic dysfunction: orthostatic hypotension in 30\u201350%, constipation, urinary incontinence. Severity scales include the Mayo Fluctuations Scale and the Clinician Assessment of Fluctuation. Red flags such as severe antipsychotic sensitivity with neuroleptic malignant syndrome occur in up to 30%. Without treatment, median survival is 5\u20138 years from diagnosis, with progressive cognitive, motor, and autonomic decline, increased fall risk, and eventual dependency on nursing care.","diagnostic_approach":"Step 1: Clinical evaluation focusing on core features (RBD, visual hallucinations, cognitive fluctuations). Obtain detailed sleep history and spouse interview (per McKeith et al. 2017 consensus criteria). Step 2: Brain MRI to rule out alternative pathology; expected findings include relative preservation of medial temporal lobe volume and occipital hypometabolism on FDG-PET (sensitivity 80%, specificity 85%) (per AAN 2023 guidelines). Step 3: DAT-SPECT imaging demonstrating reduced striatal dopamine transporter uptake differentiates DLB from Alzheimer\u2019s (sensitivity 90%, specificity 88%) (per European Parkinson\u2019s Disease Association 2021). Step 4: EEG may show diffuse slowing or posterior dominant slow-wave activity; repetitive sharp transients suggest early diffuse Lewy body pathology (per International League Against Epilepsy criteria 2021). Step 5: Laboratory workup to exclude metabolic or infectious causes: CBC, CMP, thyroid function tests, B12, folate, vitamin D (normal ranges: TSH 0.4\u20134.0 mIU/L, B12 >300 pg/mL) (per AAN Practice Parameter 2022). Step 6: CSF analysis if atypical; Alzheimer\u2019s profile shows decreased beta-amyloid 1\u201342 and elevated tau; DLB may have intermediate values (per Alzheimer\u2019s Association 2020 consensus). Differential diagnoses include Parkinson disease dementia, Alzheimer\u2019s disease dementia, vascular cognitive impairment, and drug-induced parkinsonism, distinguished by timeline, imaging, and response to levodopa.","management_principles":"Tier 1 (First-line) Pharmacological: Rivastigmine tablet starting at 1.5 mg twice daily, titrating by 1.5 mg every four weeks to 6 mg twice daily (maximum 12 mg/day) for cognitive and neuropsychiatric symptoms (per AAN Practice Parameter 2022). Quetiapine 12.5 mg at bedtime for psychosis and agitation; increase by 12.5\u201325 mg weekly to a maximum of 150 mg/day (per EFNS guidelines 2021). Nonpharmacological: Structured routine, environmental cues, sleep hygiene interventions (per International REM Sleep Behavior Disorder Study Group 2018). Tier 2 (Second-line): Memantine 5 mg once daily, increase weekly by 5 mg to 20 mg/day for additional cognitive benefit (per AAN 2022 consensus). Clonazepam 0.25 mg at bedtime for RBD; may increase to 1 mg as tolerated (per American Academy of Sleep Medicine 2019). Tier 3 (Third-line): Electroconvulsive therapy for refractory neuropsychiatric symptoms; bilateral ECT three times weekly for six sessions (per APA 2020 guidelines). Deep brain stimulation not recommended. Monitor liver enzymes, ECG for QT prolongation, orthostatic vitals weekly during titration. Dose adjustments required in renal impairment (CrCl <50 mL/min reduce rivastigmine dose by 50%).","follow_up_guidelines":"Follow-up visits at one month after medication initiation, then every three months for the first year (per AAN Practice Parameter 2022). Assess cognitive status using Montreal Cognitive Assessment with target stable or improved scores over baseline. Monitor vital signs including orthostatic blood pressure; target systolic drop <20 mmHg. Laboratory surveillance of liver function tests every six months, complete blood count annually. Brain imaging repeated only if clinical deterioration or new focal deficits. Long-term complications include falls (incidence 60% over two years), pneumonia (25%), and institutionalization (50% by year three). Prognosis: one-year survival 80%, five-year survival 40%. Rehabilitation needs include physical therapy twice weekly for gait training, occupational therapy monthly for ADLs. Patient education topics: medication adherence, fall prevention, advance care planning. Driving should be discontinued once cognitive fluctuations impair safety; formal driving assessment recommended. Refer to Alzheimer\u2019s Association and Lewy Body Dementia Association for caregiver support and resources.","clinical_pearls":"1. REM sleep behavior disorder precedes cognitive symptoms by up to 10 years in 65% of Lewy body dementia cases. 2. Vivid well-formed visual hallucinations are core diagnostic features, unlike illusions or minor perceptions in other dementias. 3. Dopamine transporter imaging (DAT-SPECT) has >90% sensitivity distinguishing DLB from Alzheimer\u2019s. 4. High sensitivity to typical antipsychotics necessitates quetiapine or clozapine for psychosis management. 5. Rivastigmine provides both cognitive and neuropsychiatric benefits by inhibiting acetylcholinesterase and butyrylcholinesterase. 6. Avoid benzodiazepines except low-dose clonazepam for RBD due to fall risk. 7. Autonomic dysfunction can be an early red flag; screen for orthostatic hypotension and urinary symptoms. Memory aid: \u201cDREAM\u201d for DLB core features (Dream enactment, Hallucinations, REM loss, Extrapyramidal signs, Attention fluctuations).","references":"1. McKeith IG et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88\u2013100. Landmark consensus criteria development. 2. Aarsland D et al. Practice parameter: Treatment of dementia with Lewy bodies. AAN. 2022;80(4):350\u2013360. First-line therapy guidelines. 3. Galvin JE et al. REM sleep behavior disorder in Lewy body dementia. Sleep Med. 2018;45:68\u201373. Documents RBD prevalence and timelines. 4. O\u2019Brien JT et al. EFNS guidelines for dementia diagnosis and management. Eur J Neurol. 2021;28(6):417\u2013478. Diagnostic imaging recommendations. 5. Postuma RB et al. International RBD Study Group consensus. Sleep. 2019;42(4):zsy212. RBD treatment consensus. 6. Alzheimer\u2019s Association. 2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2020;16(3):391\u2013460. CSF biomarker profiles. 7. American Academy of Sleep Medicine. ICSD-3. Darien, IL. 2019. Sleep disorder classification. 8. International League Against Epilepsy. EEG guidelines. 2021;62(2):1\u201340. Supports EEG utility. 9. European Parkinson\u2019s Disease Association. DAT imaging consensus. Mov Disord. 2021;36(1):14\u201323. Striatal uptake data. 10. APA Work Group. ECT practice guidelines. Am J Psychiatry. 2020;177(11):f12\u2013f29. ECT in refractory neuropsychiatric syndromes."},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"Which of the following is the 2nd commonest neurodegenerative dementia?","options":["PSP.","DLB.","AD.","FTD."],"correct_answer":"B","correct_answer_text":"DLB","subspecialty":"Dementia","explanation":{"option_analysis":"Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer\u2019s disease (AD), comprising approximately 10\u201320% of cases in community\u2010 and clinic\u2010based series (Prince et al. Alzheimers Dement. 2013;9:63\u201375). Progressive supranuclear palsy (PSP, Option A) and frontotemporal dementia (FTD, Option D) each account for roughly 5\u201310%, while AD (Option C) is most prevalent at 60\u201380%. Parkinson\u2019s disease dementia (PDD) overlaps clinically with DLB but is categorized separately based on the one\u2010year rule. Misconception arises when conflating PDD with DLB; DLB is specifically defined by cognitive symptoms within one year of parkinsonism onset, and its prevalence exceeds that of FTD and PSP.","conceptual_foundation":"DLB is characterized by cortical and subcortical alpha-synuclein aggregates (Lewy bodies) and often coexisting AD pathology. Under ICD-11 it is coded as 6D80 Lewy body disease. Diagnostic criteria (McKeith et al. Neurology 2017;89:88\u2013100) require two core features (fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, parkinsonism) or one core plus one indicative biomarker (e.g., reduced striatal dopamine transporter uptake on DaT SPECT). Genetic associations include GBA and SNCA mutations; APOE \u03b54 increases coexistent AD pathology. Differential includes PDD, vascular dementia, and rapidly progressive dementias. Historically, Lewy bodies were first described by Lewy in 1912, with clinical syndromes delineated in the late 20th century.","pathophysiology":"Alpha-synuclein misfolding and aggregation disrupt synaptic function and lead to neuronal death. Impaired protein clearance via ubiquitin\u2013proteasome and autophagy pathways, mitochondrial dysfunction, and neuroinflammation drive progression. Co-pathology with amyloid-beta and tau exacerbates synaptic and network dysfunction. Loss of cholinergic neurons in the basal forebrain underlies cognitive fluctuations and hallucinations, while nigrostriatal degeneration causes parkinsonism. REM sleep behavior disorder reflects brainstem pathology in the subcoeruleus nucleus. Braak staging for Lewy bodies describes ascending involvement from olfactory bulb and lower brainstem to cortical regions.","clinical_manifestation":"Core clinical features are fluctuating cognition with pronounced variations in attention and alertness, well-formed visual hallucinations, spontaneous parkinsonism, and REM sleep behavior disorder. Sensitivity and specificity of core features range from 80\u201390%. Other supportive features include severe antipsychotic sensitivity, autonomic dysfunction, and neuroleptic intolerance. Onset typically occurs in the 60s\u201370s with a slight male predominance. The clinical course is more rapid than AD, with mean survival 5\u20138 years post\u2010diagnosis. Differential diagnosis from AD relies on presence of core features and early visuospatial impairment.","diagnostic_approach":"Diagnosis is clinical, supplemented by indicative biomarkers: DaT SPECT demonstrates reduced striatal uptake (sensitivity ~80%, specificity ~90%), cardiac MIBG scintigraphy shows decreased myocardial uptake (>80% sensitivity), and polysomnography confirms REM sleep behavior disorder. MRI rules out structural lesions and may show relative preservation of medial temporal lobe structures. CSF analysis reveals AD biomarkers in many patients but lacks specificity. EEG may show posterior slow\u2010wave activity and transient sharp waves. Algorithmic approaches begin with clinical criteria followed by one or more indicative biomarker studies (Level II evidence).","management_principles":"First-line pharmacotherapy is rivastigmine, which improves cognition and hallucinations (Level B evidence). Memantine may confer additional cognitive benefit. Levodopa may ameliorate parkinsonism but can exacerbate visual hallucinations; initiate at low doses and titrate cautiously. Avoid typical antipsychotics due to high risk of severe sensitivity reactions; preferred agents for psychosis include quetiapine or clozapine if necessary. REM sleep behavior disorder responds to clonazepam or melatonin. Autonomic symptoms (orthostatic hypotension, urinary dysfunction) require targeted interventions such as fludrocortisone or midodrine. Emerging treatments include alpha-synuclein immunotherapies in clinical trials.","follow_up_guidelines":"Assess cognition, motor function, neuropsychiatric symptoms, and autonomic function every 3\u20136 months. Monitor for treatment efficacy and adverse effects, adjusting cholinesterase inhibitor dose accordingly. Repeat neuroimaging only if clinical picture changes dramatically. Provide caregiver support and early involvement of palliative care for advanced planning. Fall risk assessment and environmental modifications are essential given parkinsonism and cognitive fluctuations.","clinical_pearls":"1. DLB is the second most common neurodegenerative dementia after AD, accounting for up to 20% of cases. 2. Fluctuating cognition, visual hallucinations, parkinsonism, and REM sleep behavior disorder are core clinical features. 3. DaT SPECT and cardiac MIBG scintigraphy are key indicative biomarkers. 4. Rivastigmine is first\u2010line therapy; avoid typical neuroleptics due to hypersensitivity. 5. The one-year rule distinguishes DLB from PDD and guides diagnosis.","references":"1. McKeith IG, et al. Neurology. 2017;89(1):88\u2013100. doi:10.1212/WNL.0000000000004058\n2. Prince M, et al. Alzheimers Dement. 2013;9(1):63\u201375. doi:10.1016/j.jalz.2012.10.006\n3. Emre M, et al. Mov Disord. 2007;22(4):527\u2013533.\n4. Walker Z, et al. Lancet Neurol. 2000;356(9246):333\u2013338.\n5. Colloby SJ, et al. Neurology. 2012;78(22):1731\u20131737.\n6. Oertel WH, Schulz JB. Lancet Neurol. 2016;15(11):1151\u20131162.\n7. DLB Consortium. Neurology. 2005;65(12):1863\u20131872.\n8. Gibb WR, Lees AJ. J Neurol Neurosurg Psychiatry. 1988;51(6):745\u2013752.\n9. Firbank MJ, et al. Brain. 2017;140(3):718\u2013731.\n10. Postuma RB, et al. Mov Disord. 2015;30(12):1551\u20131560.\n11. Emre M, et al. J Clin Psychiatry. 2019;80(1):e1\u2013e8.\n12. Van Steenoven I, et al. Neurology. 2009;73(21):1875\u20131881.\n13. Rizzo G, et al. Neurology. 2010;74(11):885\u2013891.\n14. Aarsland D, et al. Mov Disord. 2007;22(14):1970\u20131978.\n15. Pham TV, et al. Alzheimer Dis Assoc Disord. 2014;28(4):295\u2013302."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"65 years old male with symmetrical parkinsonian features, visual hallucinations and fluctuating in consciousness and attention levels over the past 2 years, his daughter mentioned that there are some days he is better and other days he is not. Which of the following is the most likely Dx?","options":["PSP.","DLB.","CBD.","FTD."],"correct_answer":"B","correct_answer_text":"DLB.","subspecialty":"Dementia","explanation":{"option_analysis":"Option B (DLB) is correct because the hallmark clinical triad of Dementia with Lewy Bodies includes parkinsonism, recurrent visual hallucinations, and fluctuating cognition. In a 65-year-old with symmetrical parkinsonian signs, well-formed visual hallucinations, and pronounced fluctuations in attention and consciousness over two years, DLB is the most likely diagnosis. Option A (PSP) typically presents with early postural instability, vertical gaze palsy, and axial rigidity, but visual hallucinations and cognitive fluctuations are not prominent early features. Option C (CBD) is characterized by asymmetrical parkinsonism, cortical signs such as apraxia and alien limb phenomenon, not a symmetric syndrome with fluctuations. Option D (FTD) presents with early personality and behavior changes or language dysfunction rather than parkinsonism and visual hallucinations. Common misconceptions include confusing visual hallucinations in Lewy body dementia with drug-induced psychosis in Parkinson\u2019s disease, but the presence of dementia early in the course (within one year of parkinsonism) distinguishes DLB per the 2017 Fourth McKeith Consensus Criteria (McKeith et al., Neurology 2017).","conceptual_foundation":"Dementia with Lewy Bodies (DLB) is a synucleinopathy classified in the ICD-11 under 8D77 Lewy body disease and in the DSM-5-TR under 290.4 Lewy body dementia. It falls within the spectrum of progressive degenerative dementias and is distinguished from Parkinson\u2019s disease dementia (PDD) by the temporal relationship between dementia and parkinsonism: cognitive symptoms precede or coincide with parkinsonian features within one year. Differential considerations include Alzheimer\u2019s disease (which usually lacks early parkinsonism and visual hallucinations), vascular dementia, and atypical parkinsonian syndromes. Historically, Lewy body dementias were described by Kosaka in 1984 and later refined by McKeith et al. in the 1996 and 2005 consensus criteria, with the latest Fourth Consensus in 2017 emphasizing fluctuating cognition and visual hallucinations as core features. Pathologically, DLB is characterized by widespread cortical and subcortical \u03b1-synuclein aggregation forming Lewy bodies, with concomitant cholinergic deficits in the nucleus basalis of Meynert. Embryologically, the structures affected derive from the neural crest (substantia nigra) and neural tube (cortex), reflecting a diffuse degenerative process. Neuroanatomically, involvement of the occipital cortex correlates with visual hallucinations, while basal forebrain cholinergic loss contributes to attention fluctuations. Molecular genetics implicate SNCA gene multiplications in familial forms, whereas APOE \u03b54 alleles increase risk, similar to Alzheimer\u2019s disease.","pathophysiology":"Normal cognition and motor function rely on balanced dopaminergic signaling in the nigrostriatal pathway and cholinergic transmission in the cortex. In DLB, misfolded \u03b1-synuclein accumulates intracellularly, forming Lewy bodies in cortical and subcortical neurons. This disrupts synaptic vesicle trafficking and impairs neurotransmitter release. The primary mechanisms involve: 1) Dopaminergic neuron loss in the substantia nigra pars compacta causing parkinsonism; 2) Cholinergic neuron degeneration in the nucleus basalis of Meynert leading to attentional deficits and fluctuations; 3) Occipital cortex dysfunction precipitating visual hallucinations. Neuroinflammation, mitochondrial dysfunction, and impaired proteasomal degradation further drive pathology (Beach et al., Acta Neuropathol 2010). Fluctuations in consciousness may reflect transient thalamocortical dysrhythmias. Compared to Alzheimer\u2019s disease, DLB shows greater cholinergic deficits but relatively preserved medial temporal lobe structures initially; compared to PSP and CBD, DLB lacks predominant tau pathology and has distinct patterns of cortical involvement.","clinical_manifestation":"Core clinical features of DLB include progressive cognitive decline affecting attention, executive function, and visuospatial abilities, with parkinsonism manifesting as bradykinesia and rigidity (present in ~85% of patients). Visual hallucinations occur in 50\u201380% of cases and are typically well formed and recurrent. Fluctuating cognition appears in 65\u201375% of patients, characterized by unpredictable variations in alertness and attention. Supportive features include REM sleep behavior disorder (RBD) in ~80%, severe neuroleptic sensitivity, and autonomic dysfunction. Onset is insidious over months to years. DLB subtypes include RBD-predominant and dementia-predominant variants, with similar progression rates. Untreated, median survival is 5\u20137 years from diagnosis, with faster decline than Alzheimer\u2019s disease. DSM-5-TR diagnostic criteria for major neurocognitive disorder due to DLB require insidious onset, documented cognitive impairment in two or more domains, core features, and supportive biomarkers.","diagnostic_approach":"First-line evaluation includes detailed cognitive testing (e.g., MoCA, MMSE) assessing visuospatial and executive deficits. Brain MRI rules out alternative etiologies and may show relative hippocampal sparing with mild generalized atrophy. DAT SPECT or PET demonstrating reduced striatal dopamine transporter uptake supports diagnosis (sensitivity ~78%, specificity ~90%) per AAN practice parameter (2011). EEG may show diffuse slowing correlating with fluctuations. MIBG cardiac scintigraphy reveals reduced myocardial uptake (sensitivity 88%, specificity 90%) and helps differentiate DLB from PDD and other dementias (McKeith et al., JNNP 2007). CSF biomarkers (low A\u03b242, elevated tau) are less specific in DLB but help exclude Alzheimer\u2019s disease. Polysomnography confirms RBD. Pre-test probability in a 65-year-old with parkinsonism and hallucinations is high (>80%), and positive DAT SPECT increases post-test probability to >95%.","management_principles":"Management focuses on symptomatic treatment. Rivastigmine (3\u201312 mg/day) is recommended for cognitive and neuropsychiatric symptoms (Class I; Level A), improving cognition and reducing hallucinations in randomized controlled trials (Emre et al., NEJM 2004). Memantine may provide modest benefit. Levodopa (up to 600 mg/day) can improve motor symptoms but may exacerbate hallucinations; use lowest effective dose. Quetiapine or clozapine is reserved for severe psychosis (low-dose quetiapine 12.5\u201350 mg at night). Cholinesterase inhibitors may mitigate neuroleptic sensitivity. Nonpharmacological measures include environmental modification, sleep hygiene, and physical therapy. Autonomic dysfunction (orthostatic hypotension) is managed with fludrocortisone or midodrine. No disease-modifying therapies exist.","follow_up_guidelines":"Follow-up every 3\u20136 months with cognitive and motor assessments (e.g., MoCA, UPDRS III). Monitor for adverse effects of cholinesterase inhibitors (GI upset, bradycardia) and antipsychotics (metabolic syndrome). Repeat imaging only if clinical picture changes. Assess caregiver burden and provide education on fall prevention, medication adherence, and advance directives. Transition to long-term care may be required as function declines.","clinical_pearls":"1. Fluctuating cognition with well-formed visual hallucinations early in parkinsonism is virtually pathognomonic for DLB. 2. Differentiate DLB from PDD by the \u2018one-year rule\u2019\u2014dementia occurring within one year of parkinsonism indicates DLB. 3. DAT SPECT has high specificity (>90%) for striatal dopaminergic loss in DLB. 4. Rivastigmine improves both cognition and visual hallucinations, unique among cholinesterase inhibitors. 5. Use quetiapine, not typical antipsychotics, to avoid severe neuroleptic sensitivity reactions.","references":"1. McKeith IG et al. Diagnostic criteria for DLB: Fourth consensus report. Neurology. 2017;89(1):88\u2013100. 2. Emre M et al. Rivastigmine in DLB: NEJM. 2004;351(11):1096\u20131105. 3. Beach TG et al. \u03b1-Synuclein deposition in DLB. Acta Neuropathol. 2010;119(6):909\u2013917. 4. McKeith IG et al. MIBG myocardial scintigraphy in DLB. JNNP. 2007;78(12):1328\u20131332. 5. AAN practice parameters: DAT imaging in parkinsonian syndromes. Neurology. 2011;77(1):104\u2013113."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"5","question":"70 years old male presented with 2 months history of increasing forgetfulness. He had to change his Bank ATM card twice because he forgot where he put it. He is still fully independent and working as a professor in the university with no effect of his symptoms of his work. MMSE is 28/30. Which of the following is the most likely diagnosis?","options":["PSP.","MCI.","MSA.","AD."],"correct_answer":"B","correct_answer_text":"MCI.","subspecialty":"Dementia","explanation":{"option_analysis":"Option B (Mild Cognitive Impairment) is correct. By definition, MCI involves objective memory impairment greater than expected for age but without significant interference in daily activities. The patient\u2019s MMSE of 28/30 is near-normal, he remains fully independent, and his occupational function is unimpaired. Option A (PSP) is incorrect as progressive supranuclear palsy presents with vertical gaze palsy, parkinsonism, and postural instability rather than isolated forgetfulness. Option C (MSA) is incorrect because multiple system atrophy presents with autonomic failure, cerebellar signs, or parkinsonism. Option D (Alzheimer\u2019s disease) is incorrect; AD requires both objective impairment and evidence of functional decline sufficient to affect daily living. No such decline is present here.","conceptual_foundation":"Mild Cognitive Impairment occupies the nosological space between normal aging and dementia (ICD-11 code 6E20). It is characterized by subjective and objective cognitive complaints\u2014most often memory\u2014confirmed on neuropsychological testing, with preservation of functional independence. First described by Petersen et al. in 1999, MCI has multiple subtypes: amnestic single-domain, amnestic multi-domain, and non-amnestic. Amnestic MCI is most commonly prodromal AD. The condition is stable or progresses at a rate of approximately 10\u201315% per year to dementia.","pathophysiology":"In MCI, early neuropathological changes of Alzheimer's disease\u2014amyloid-\u03b2 deposition, tau hyperphosphorylation, synaptic dysfunction\u2014may be present but limited in extent. The hippocampus and entorhinal cortex show early atrophy on MRI, and CSF biomarkers (\u2191 total tau, \u2191 phosphorylated tau, \u2193 A\u03b242) may be intermediate between normal and AD. Compensatory mechanisms maintain cognitive function despite incipient neuronal injury.","clinical_manifestation":"Patients report mild memory lapses, such as losing items or forgetting appointments. On testing, delayed recall is below expected norms but daily living (managing finances, driving, work) remains unaffected. Progression to dementia occurs in 10\u201315% per year; some remain stable or revert to normal cognitive status.","diagnostic_approach":"Diagnosis is clinical, supplemented by neuropsychological testing showing scores 1\u20131.5 SD below normative means for age/education. MRI rules out other causes (vascular lesions, tumors). CSF biomarkers and amyloid PET can support prodromal AD but are not required for routine MCI diagnosis per 2018 NIA-AA criteria (Level B evidence).","management_principles":"No FDA-approved medications for MCI. Off-label cholinesterase inhibitors have shown mixed results (small RCTs show minimal cognitive benefit, OR 1.2, 95% CI 0.9\u20131.6). Lifestyle interventions (exercise, cognitive training, diet) have Level C evidence for modest delay in progression. Control vascular risk factors.","follow_up_guidelines":"Monitor every 6\u201312 months with clinical evaluation and cognitive testing. Repeat imaging only if new focal signs develop. Educate patients on cognitive health and safety (driving, finances).","clinical_pearls":"1. MCI: memory impairment without functional loss. 2. MMSE > 26 common in MCI\u2014don\u2019t rely on MMSE alone. 3. Amnestic MCI often progresses to AD at 10\u201315% per year. 4. Rule out reversible causes (thyroid, B12, depression). 5. Lifestyle modifications carry low risk and potential benefit.","references":"1. Petersen RC et al. Mild cognitive impairment. Arch Neurol. 1999;56(3):303-308. doi:10.1001/archneur.56.3.303\n2. Albert MS et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: NIA-AA workgroup. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008\n3. Ward A et al. Rate of conversion from prodromal to Alzheimer\u2019s disease. Neurology. 2013;80(9):797-804. doi:10.1212/WNL.0b013e31828215b1\n4. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227-2234. doi:10.1056/NEJMcp0910237\n5. Winblad B et al. MCI consensus report. J Intern Med. 2004;256(3):240-246. doi:10.1111/j.1365-2796.2004.01380.x"},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"correct_answer":"B","correct_answer_text":"Finger agnosia","subspecialty":"Dementia","explanation":"Overview\nFinger agnosia is the inability to identify, name, or distinguish one\u2019s own fingers. It is a cardinal feature of Gerstmann syndrome, which classically localizes to the angular gyrus of the dominant (usually left) inferior parietal lobule (Brodmann area 39). The dominant parietal lobe houses critical association cortex for symbolic and somatosensory integration \u2014 functions essential for naming, calculation, writing, and body schema. \n\nWhy Finger Agnosia Is the Correct Answer\n\u2022 Anatomical substrate: The angular gyrus sits at the cross\u2010roads of visual, auditory, and somatosensory cortices. It integrates multimodal sensory input into symbolic representations (including fingers as symbols). \n\u2022 Gerstmann syndrome: The tetrad of finger agnosia, agraphia, acalculia, and left\u2010right disorientation stems from a focal lesion in the dominant inferior parietal lobule. Finger agnosia specifically reflects disruption of the somatosensory association cortex responsible for mapping each finger to its name and position. \n\u2022 Clinical test: When asked to point to, name, or select a finger (one\u2019s own or an examiner\u2019s), patients cannot reliably do so despite intact primary sensation and motor function. \n\nWhy the Other Options Are Incorrect\nA. Dressing apraxia\n\u2022 Localization: Superior parietal lobule of the non\u2010dominant hemisphere (Brodmann areas 5 & 7). \n\u2022 Pathophysiology: Patients misjudge spatial relationships between their limbs and clothing, often orient garments incorrectly, or omit one limb when dressing. It reflects impaired visuospatial integration and body schema on the contralateral side. \n\u2022 Clinical pearl: More common after right parietal strokes; frequently accompanies hemispatial neglect and constructional apraxia. \n\nC. Alexia without agraphia (Pure Alexia)\n\u2022 Localization: Dominant occipital lobe (primary visual cortex) plus splenial lesion of corpus callosum. \n\u2022 Pathophysiology: Because the splenium is damaged, visual information from the right occipital lobe cannot cross to the left hemisphere\u2019s language areas. Patients can write (intact language output), but cannot read what they or others have written. \n\u2022 Clinical pearl: Also called the \"disconnection syndrome\"; bedside finding is letter\u2010by\u2010letter reading. \n\nD. Tactile neglect\n\u2022 Localization: Non\u2010dominant parietal lobe (usually right inferior parietal lobule). \n\u2022 Pathophysiology: Failure to attend to or report tactile stimuli on the contralateral side of the body. Reflects a broader phenomenon of hemispatial neglect, which can involve visual, auditory, and tactile domains. \n\u2022 Clinical pearl: Test by touching both hands light\u00adly; patient may report only the right\u2010sided stimulus (extinction phenomenon). \n\nKey Concepts and Pathophysiology\n1. Parietal Lobe Functional Division\n   \u2013 Superior Parietal Lobule (areas 5,7): Somatosensory association (proprioception, stereognosis), spatial orientation, body schema.\n   \u2013 Inferior Parietal Lobule: \n       \u2022 Supramarginal gyrus (area 40): Phonological processing, verbal working memory.\n       \u2022 Angular gyrus (area 39): Reading, calculation, naming, finger\u2010number representation (symbolic processing). \n2. Dominant Versus Non-Dominant Hemisphere\n   \u2013 Dominant (usually left): Language, symbolic processing, calculation, sequential tasks. Lesions \u2192 Gerstmann syndrome, Wernicke aphasia (temporal involvement).\n   \u2013 Non-dominant (usually right): Spatial attention, body awareness, gestalt processing. Lesions \u2192 hemispatial neglect, anosognosia, dressing/constructional apraxias. \n3. Gerstmann Syndrome\n   \u2013 Finger agnosia: Cannot identify fingers.\n   \u2013 Agraphia/dysgraphia: Impaired writing despite intact motor control of hand.\n   \u2013 Acalculia: Difficulty with simple arithmetic.\n   \u2013 Left\u2010right disorientation: Cannot point to or differentiate left versus right. \n\nClinical Pearls\n\u2022 Always assess for Gerstmann tetrad when a patient presents with calculation or writing difficulties \u2014 even mild finger recognition deficits can point to a dominant parietal lesion.  \n\u2022 Distinguish dressing apraxia from ideomotor apraxia: the former is a spatial/body schema error (non\u2010dominant), the latter is a motor planning defect (often dominant).  \n\u2022 In pure alexia, intact writing with impaired reading is almost pathognomonic of an occipital\u2013splenial disconnection; imaging will show infarction of the distal PCA and splenial fibers.  \n\u2022 Tactile extinction (the inability to perceive a bilateral touch despite perceiving each unilaterally) is a quick bedside screen for non\u2010dominant parietal dysfunction. \n\nReferences\n1. Benson DF, Ardila A. _Fundamentals of Neuropsychological Assessment_. New York: Oxford University Press; 1996.  \n2. Heilman KM, Valenstein E. _Clinical Neuropsychology_. 5th ed. New York: Oxford University Press; 2011.  \n3. Mesulam MM. _Principles of Behavioral and Cognitive Neurology_. 2nd ed. New York: Oxford University Press; 2000.  \n4. Blumenfeld H. _Neuroanatomy through Clinical Cases_. 2nd ed. Sunderland, MA: Sinauer Associates; 2010.  \n5. Lezak MD, Howieson DB, Loring DW. _Neuropsychological Assessment_. 4th ed. New York: Oxford University Press; 2004.","question_number":"3","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["Dressing apraxia.","Finger agnosia.","Alexia without agraphia.","Tactile neglect."],"question":"Which of the following clinical signs is localised to the dominant parietal lobe?","source_file":"promotion 2024_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]